Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01)

AstraZeneca

Status and phase: Enrolling; Phase 2

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: Carboplatin; Drug: Pemetrexed; Drug: Volrustomig

Study type: Interventional

Funder types: Industry

Identifiers

NCT06448754

2023-509482-20-00 (Registry Identifier)

D798KC00001

Details and patient eligibility

About

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Full description

This is a platform, randomized, open-label, multicenter, global study.

Enrolled participants with Stage IV non-squamous non-small cell lung cancer (NSQ NSCLC) who are treatment-naïve and have not received previous treatment for advanced or metastatic disease.

These participants will be randomized in a 1:1 ratio to one of the two treatment arms: Arm 1A and Arm 1B.

Both arms will test a volrustomig dosing in combination with chemotherapy.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
• Life expectancy greater than or equal to (>=) 12 weeks.
• Adequate organ and bone marrow function.
• Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
• Histologically or cytologically documented NSQ NSCLC.
• Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
• Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
• At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.

Key Exclusion Criteria:

• Spinal cord compression.
• History of primary active immunodeficiency.
• Active or prior documented autoimmune or inflammatory disorders.
• Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
• Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
• Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

120 participants in 2 patient groups

Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed

Experimental group

Description:

Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.

Treatment:

Drug: Volrustomig

Drug: Pemetrexed

Drug: Carboplatin

Arm 1 B Volrustomig dose regimen 2 + Carboplatin and Pemetrexed

Experimental group

Description:

Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.

Treatment:

Drug: Volrustomig

Drug: Pemetrexed

Drug: Carboplatin